41. *300247 BONE MORPHOGENETIC PROTEIN 15; BMP15 Xlinked mutation that causes increased ovulation rate and twin and triplet births in heterozygotes, but primary ovarian failure in homozygotes. http://srs.sanger.ac.uk/srsbin/cgi-bin/wgetz?[omim-ID:300247] -e

42. DISEASES OF OTHER ENDOCRINE GLANDS 256.31 Premature menopause 256.39 Other ovarian failure Delayed menarche Ovarian hypofunction primary ovarian failure NOS http://www.thera.info/icd9-cm/sect-250-259.html

DISEASES OF OTHER ENDOCRINE GLANDS (250-259) Diabetes mellitus Other disorders of pancreatic internal secretion Disorders of parathyroid gland Disorders of the pituitary gland and its hypothalamic control ... Other endocrine disorders 250 Diabetes mellitus Excludes: gestational diabetes (648.8) hyperglycemia NOS (790.6) neonatal diabetes mellitus (775.1) nonclinical diabetes (790.2) The following fifth-digit subclassification is for use with category 250: type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled Fifth-digit is for use for type II, adult-onset, diabetic patients, even if the patient requires insulin 1 type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled 2 type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled Fifth-digit II is for use for type II, adult-onset, diabetic patients, even if the patient requires insulin 3 type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled 250.0 Diabetes mellitus without mention of complication

43. RxMed: Pharmaceutical Information - GONAL primary ovarian failure should be excluded by the determination of gonadotropin levels. Pregnancy Appropriate evaluation should be performed to exclude http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS- Monographs/CP

GONAL-F® Serono Follitropin alpha (rDNA origin) Gonadotropin Action And Clinical Pharmacology: Gonal-F is a gonadotropin preparation of recombinant DNA origin. The active ingredient, recombinant human follicle stimulating hormone (r-hFSH), is a human glycoprotein hormone which consists of 2 noncovalently linked, nonidentical protein components designated as the a- and b-subunits. The physicochemical, immunological, and biological activities of r-hFSH are similar to those of human menopausal urine-derived hFSH, but free of urinary protein and of any LH component. Gonal-F stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH is the primary hormone responsible for follicular recruitment and development. To complete follicular maturation and effect ovulation in the absence of an endogenous luteinizing hormone (LH) surge, human chorionic gonadotropin (hCG) is given when monitoring of the patient indicates that sufficient follicular development has occurred. There may be a degree of interpatient variability in response to FSH administration, with lack of response to FSH in some patients. Pharmacokinetics: Following i.v. administration, follitropin alpha (rDNA origin) is distributed to the extracellular fluid space with an initial half-life around 2 hours and eliminated from the body with a terminal half-life of about 1 day. The steady-state volume of distribution and total clearance are 10 L and 0.6 L/h, respectively. One-eighth of the follitropin alpha (rDNA origin) dose is excreted in the urine.

44. RxMed: Pharmaceutical Information - HUMEGON of anovulation is functional and not due to primary ovarian failure. A high level of urinary gonadotropins indicating primary ovarian failure. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS- Monographs/CP

HUMEGON® Organon Human Gonadotropin Human Gonadotropins Action And Clinical Pharmacology: Humegon (human gonadotropin) is a purified preparation of gonadotropins extracted from the urine of post menopausal and pregnant women. It contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both of which are necessary for the normal gamete maturation (follicle ripening in the female and spermatogenesis in the male) and for gonadal steroid production. Unlike menotropins, human gonadotropin is standardized with hCG. Human gonadotropin is used to stimulate these processes in selected cases of disturbed gonadal function. It is generally used in combination with a gonadotropin with LH activity, such as human chorionic gonadotropin (hCG). The combined treatment may be either sequential (in the case of ovulation induction) or concomitant (in the case of Leydig cell stimulation). tag_IndicationsIndications Indications And Clinical Uses: Women: Human gonadotropin and human chorionic gonadotropin (hCG) given sequentially are indicated for the induction of ovulation and pregnancy in females infertile due to anovulation where the cause of anovulation is functional and not due to primary ovarian failure. Men: Human gonadotropin and concomitant hCG is indicated for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism.

45. Human FSH (hFSH) - Cycle, Estrogen, Fertility, Multiple, Ovarian, PCOS, Primary, No current pregnancy; No evidence of primary ovarian failure; No uncontrolled thyroid or adrenal dysfunction; No ovarian cysts (except in case of PCOS) http://www.infertilitycentral.com/fertility/human-fsh-hfsh.html

@import url(http://www.infertilitycentral.com/uni/infertilitycentral/styles/common.css); @import url(http://www.infertilitycentral.com/uni/infertilitycentral/styles/screen.css); @import url(http://www.infertilitycentral.com/uni/infertilitycentral/styles/nav.css); Infertility Treatment Human FSH (hFSH) Classification Human urofollitropins Brand Names Fertinex®, Metrodin HP® (mfg. Serono) Form Subcutaneous injection Indications Demonstrated ovulatory dysfunction with: No current pregnancy No evidence of primary ovarian failure No uncontrolled thyroid or adrenal dysfunction No ovarian cysts (except in case of PCOS) Used in conjunction with hCG Used for In women, inducing ovarian follicular growth and maturation. May be particularly useful for women with PCOS (polycystic ovarian syndrome). How does it work? Possesses hormonal activities of follicle stimulating hormone (FSH). Suggested Evaluations Pre-RX thyroid disease ovarian enlargement or cyst formation uterine fibroid tumors undiagnosed unusual vaginal bleeding estrogen levels primary pituitary or ovarian failure or enlargement evidence of prostate cancer in men testicular failure renal and hepatic functions During RX mid-cycle urine LH test (OPK) estrogen levels progesterone levels mid-cycle ultrasound to detect follicle development Usual Dosage Dosage must be carefully determined for each patient, and may be changed during treatment cycle.

46. ICD-9-CM From Code 250 Ovarian failure. iatrogenic; postirradiation; postsurgical. 256.3 Other ovarian failure. Premature menopause NOS; primary ovarian failure http://www.dmi.columbia.edu/hripcsak/icd9/1tabular250.html

DISEASES OF OTHER ENDOCRINE GLANDS (250-259) 250 Diabetes mellitus Excludes: gestational diabetes (648.8) hyperglycemia NOS (790.6) neonatal diabetes mellitus (775.1) nonclinical diabetes (790.2) that complicating pregnancy, childbirth, or the puerperium (648.0) The following fifth-digit subclassification is for use with category 250: 0 type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled 1 type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled 2 type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled 3 type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled 250.0 Diabetes mellitus without mention of complication Diabetes mellitus without mention of complication or manifestation classifiable to 250.1-250.9 Diabetes (mellitus) NOS 250.1 Diabetes with ketoacidosis Diabetic: acidosis without mention of coma ketosis without mention of coma 250.2 Diabetes with hyperosmolarity Hyperosmolar (nonketotic) coma 250.3 Diabetes with other coma

47. Humegon primary ovarian failure should be excluded by the determination of gonadotropin levels. A high FSH level indicating primary ovarian failure. http://www.druginfonet.com/humegon.htm

Humegon™ (menotropins for injection, USP) FOR INTRAMUSCULAR INJECTION DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE CONTRAINDICATIONS ... HOW SUPPLIED DESCRIPTION Humegon™ (menotropins for injection, USP) is a purified preparation of gonadotropins. Menotropins are extracted from the urine of postmenopausal females and possess follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. The ratio of FSH bioactivity and LH bioactivity in menotropins is adjusted to approximate unity by the addition of human chorionic gonadotropin purified from the urine of pregnant women. Each vial of Humegon™ contains 75 IU or 150 IU of follicle-stimulating hormone activity and 75 IU or 150 IU of luteinizing hormone activity, respectively, plus 10.5 mg lactose, hydrous NF; 0.25 mg monosodium phosphate, monohydrate USP; 0.25 mg disodium phosphate, anhydrous USP; sodium hydroxide NF or phosphoric acid NF to adjust pH; in a sterile, lyophilized form. Humegon™ is administered by intramuscular injection. Humegon™ is biologically standardized for FSH and LH gonadotropin activities and the potencies are based on the results of in vivo bioassay, which are in agreement with the recommendations of the World Health Organization Expert Committee on Biological Standardization (1982).

48. Internet Scientific Publications, LLC. Hypergonadotropic hypogonadism is caused by primary ovarian failure associated with elevated gonadotropin levels. An elevated FSH will establish the http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijgo/vol4n1/menstrual.

49. Ogen Indications, Dosage, Storage, Stability - Estropipate - RxList Monographs Female castration or primary ovarian failure— A daily dose of one OGEN 1.25 (1.5 mg estropipate) tablet to three OGEN 2.5 (3 mg estropipate) tablets may be http://www.rxlist.com/cgi/generic/ogen_ids.htm

document.writeln(''); document.writeln(''); Estropipate document.writeln(''); document.writeln(''); Company Issues Pacemaker Malfunction Warning Deaths Seen With Fentanyl Narcotic Pain Patch FDA Reviews Adult Antidepressant-Suicide Link INDICATIONS Estrogen drug products are indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. There is no adequate evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause and they should not be used to treat these conditions. 2. Treatment of vulval and vaginal atrophy. 3. Treatment of hypoestrogenism due to hypogonadism , castration or primary ovarian failure. document.writeln(''); 4. Prevention of osteoporosis. Since estrogen administration is associated with risk, selection of patients should ideally be based on prospective identification of risk factors for developing osteoporosis. Unfortunately, there is no certain way to identify those women who will develop osteoporotic fractures. Most prospective studies of efficacy for this indication have been carried out in white menopausal women, without stratification by other risk factors, and tend to show a universally salutary effect on bone. Thus, patient selection must be individualized based on the balance of risks and benefits. A more favorable risk/benefit ratio exists in a hysterectomized woman because she has no risk of

50. Premarin Indications, Dosage, Storage, Stability - Estrogens Conjugated - RxList Female Castration or primary ovarian failure 1.25 mg daily, cyclically. Adjust dosage, upward or downward, according to severity of symptoms and response http://www.rxlist.com/cgi/generic/conest_ids.htm

document.writeln(''); document.writeln(''); Estrogens Conjugated document.writeln(''); document.writeln(''); Company Issues Pacemaker Malfunction Warning Deaths Seen With Fentanyl Narcotic Pain Patch FDA Reviews Adult Antidepressant-Suicide Link INDICATIONS Tablets Conjugated estrogens tablets are indicated in the treatment of: Moderate to severe vasomotor symptoms associated with the menopause. There is no adequate evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause and they should not be used to treat these conditions. Atrophic vaginitis. document.writeln(''); Osteoporosis (loss of bone mass). The mainstays of prevention and management of osteoporosis are estrogen and calcium; exercise and nutrition may be important adjuncts. Estrogen replacement therapy is the most effective single modality for the prevention of osteoporosis in women. Estrogen reduces bone resorption and retards or halts postmenopausal bone loss. Case-controlled studies have shown an approximately 60-percent

51. Ferring Pharmaceuticals - Fertility Products in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins. http://www.ferringusa.com/fertility_products/insert_novarel.htm

Home Contact Overview of Products Bravelle Information ... Infertility Overview Novarel (chorionic gonadotropin for injection, USP) Package Insert Novarel (Chorionic Gonadotropin for Injection, USP) FOR INTRAMUSCULAR USE ONLY Rx Only TABLE OF CONTENTS Description Clinical Pharmacology Indications and Usage Contraindications ... How Supplied DESCRIPTION: Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta, is composed of an alpha and a beta sub-unit. The alpha sub-unit is essentially identical to the alpha sub-units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit of human thyroid-stimulating hormone (TSH). The beta sub-units of these hormones differ in amino acid sequence. Chorionic Gonadotropin is a water soluble glycoprotein derived from human pregnancy urine. The sterile lyophilized powder is stable. When reconstituted with Bacteriostatic Water for Injection preserved with benzyl alcohol 0.9%, the solution should be refregerated and used within 30 days. Each vial contains: Chorionic Gonadotropin USP Units

52. Pregnancies After Oocyte Donation In Women With Ovarian Failure Caused By An Ina (1996) Clinical features of primary ovarian failure caused by a point mutation in the folliclestimulating hormone receptor gene. J. Clin. Endocr. http://humrep.oxfordjournals.org/cgi/content/full/17/1/124

JOURNAL HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This Article Abstract FREE Full Text (PDF ) Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed ... Download to citation manager Search for citing articles in: ISI Web of Science (2) Request Permissions PubMed PubMed Citation Articles by Hovatta, O. Human Reproduction, Vol. 17, No. 1, 124-127, January 2002 European Society of Human Reproduction and Embryology Pregnancies after oocyte donation in women with ovarian failure caused by an inactivating mutation in the follicle stimulating hormone receptor Outi Hovatta Tuija Foudila Leena Tuomivaara Kaisa Juntunen Aila Tiitinen and The Infertility Clinic of the Family Federation of Finland in Helsinki and Oulu, Department of Gynaecology and Obstetrics and Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland and

53. Society : - Leukemia Chemotherapy can also cause primary ovarian failure, but it usually takes very high doses to cause damage. Premature menopause has been noted in some female http://www.leukemia-lymphoma.org/all_mat_toc.adp?item_id=9965&cat_id=1214

54. FDA Drug Approvals List  August 1998 symptoms associated with menopause; 2. Vulvar and vaginal atrophy; and 3. Hypoestrogenism due to hypogonadism, castration or primary ovarian failure http://www.fda.gov/cder/da/da0898.htm

Drug Approvals for August 1998 Definitions and Notes August 1998 Original New Drug Applications Original Application #: Approval Date: 26-AUG-98 Trade Name: VITRAVENE Chemical Type: Therapeutic Potential: P Dosage Form: INJECTABLE Applicant: ISIS PHARMACEUTICALS INC Active Ingredient(s): FOMIVIRSEN SODIUM OTC/RX Status: RX Indication(s): Local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis Original Application #: Approval Date: 26-AUG-98 Trade Name: PROSOL 20% IN PLASTIC CONTAINER Chemical Type: Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: BAXTER HEALTHCARE CORP Active Ingredient(s): AMINO ACIDS OTC/RX Status: RX Indication(s): (1) As an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance in patients where: the alimentary tract cannot or should not be used; gastrointestinal absorption of protein is impaired; or metabolic requirements for protein are substantially increased, as with extensive burns; (2) To reduce fluid intake in patients who require both fluid restriction and total parenteral nutrition (TPN) Original Application #: Approval Date: 24-AUG-98 Trade Name: LAMICTAL Chemical Type: Therapeutic Potential: S Dosage Form: TABLET,CHEWABLE DISPERSIBLE

55. Newly Approved Drug Therapies (647): Ovidrel (gonadotropin, Chorionic Human Reco the cause of infertility is functional and not due to primary ovarian failure. primary ovarian failure; uncontrolled thyroid or adrenal dysfunction http://www.centerwatch.com/patient/drugs/dru647.html

Description of Medical Areas About the FDA Approved Listings Drugs Approved by the FDA Drug Name: Ovidrel (gonadotropin, chorionic human recombinant) The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Company: Serono Laboratories Approval Status: Approved September 2000 Treatment for: Infertility General Information Ovidrel has been approved for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program. Also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. (From FDA Label) It is available by prescription only and is in an injectable formulation. Clinical Results Two assisted reproductive technologies (ART) studies were held to evaluate the safety and efficacy of Ovidrel at two dosage levels, 250mcg and 500mcg. The drug was administered subcutaneously in a randomized, open-label, 20 center study to infertile women undergoing

56. Vaginal Progesterone: From IVF To Menopause Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 1990;5537543. http://www.gfmer.ch/Presentations_En/Vaginal_progesterone.htm

Vaginal progesterone: from IVF to menopause Dominique de Ziegler Hôpital de Nyon and Department of Obstetrics and Gynecology, Geneva University Hospital 1. Vaginal progesterone: the only practical option to avoid painful IM injections. The original preparations used for administering progesterone vaginally were locally made cocoa butter-based suppositories or products designed for oral use. Today, a vaginal progesterone gel, Crinone 8%, was recently developed and found as effective as IM progesterone in either, actual donor egg IVF cycles or a large multi-center trial conducted in regular IVF. vaginal progesterone was found to be as effective as IM progesterone. 2. Vaginal progesterone: a direct access to the uterus through a newly discovered functional "portal" system The recent development of a new sustained release vaginal progesterone gel, Crinone 4%, showed that using less progesterone (because of the sustained release effects) nonetheless achieved endometrial results similar to findings made with IM progesterone administration or in the menstrual cycle. This led to the unexpected discovery of uterine trophicity of vaginal progesterone. In a prospective trial, Fanchin et al. (4) demonstrated that every other day administration of 1.1 g of Crinone 4% gel containing 45 mg of progesterone induced full endometrial decidualization, despite progesterone levels in peripheral blood that were in the "luteal phase defect" range (peaks at < 5 ng/mL and troughs at ≤ 1 ng/mL).

57. Follicle Stimulating Hormone Is Required For Ovarian Follicle Maturation But Not Clinical features of primary ovarian failure caused by a point mutation in the folliclestimulating hormone receptor gene. J. Clin. Endocr. Metab. http://www.nature.com/ng/journal/v15/n2/abs/ng0297-201.html

@import "/ng/style.css"; NATURE.COM NEWS@NATURE.COM NATUREJOBS NATUREEVENTS ... Help E-MAIL: PASSWORD: Save password Forgotten password? SEARCH JOURNAL Advanced search Journal home Archive Table of Contents ... For librarians NPG Resources Nature Nature Cell Biology Nature Medicine Nature Reviews Genetics ... Browse all publications Letter Nature Genetics doi:10.1038/ng0297-201 Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility T. Rajendra Kumar , Yan Wang , Naifang Lu Departments of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA. Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA. e-mail: mmatzuk@bcm.tmc.edu. Follicle stimulating hormone (FSH) is a member of the glycoprotein hormone family that includes luteinizing hormone (LH), thyroid stimulating hormone, and chorionic gonadotropin. These heterodimeric hormones share a common subunit and differ in their hormone-specific subunit. The biological activity is conferred only by the heterodimers. FSH and LH are synthesized in the same cells of the pituitary, the gonadotrophs1,2. FSH receptors are localized to Sertoli cells of the testes and granulosa cells of the ovary1,2. Minimal data has been accumulated so far involving human mutations in the FSH

58. III. ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES, AND IMMUNITY 9 256.3 Other ovarian failure Premature menopause NOS primary ovarian failure 256.4 Polycystic ovaries SteinLeventhal syndrome 256.8 Other 256.9 http://www.nber.org/mortality/1995/docs/ch03.txt

III. ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES, AND IMMUNITY DISORDERS Excludes: endocrine and metabolic disturbances specific to the fetus and newborn (775.-) Note: All neoplasms, whether functionally active or not, are classified in Chapter 2. Codes in Chapter 3 (i.e., 242.8, 246.0, 251-253, 255-259) may be used, if desired, to identify such functional activity associated with any neoplasm, or by ectopic endocrine tissue. DISORDERS OF THYROID GLAND (240-246) 240 Simple and unspecified goiter 240.0 Goiter, specified as simple Includes: conditions in 240.9, specified as simple 240.9 Goiter, unspecified Enlargement of thyroid Goiter or struma: NOS diffuse colloid endemic hyperplastic parenchymatous Excludes: congenital (dyshormonogenic) goiter (246.1) 241 Nontoxic nodular goiter Excludes: adenoma of thyroid (226) cystadenoma of thyroid (226) 241.0 Nontoxic uninodular goiter Thyroid nodule Uninodular goiter (nontoxic) 241.1 Nontoxic multinodular goiter Multinodular goiter (nontoxic) 241.9 Unspecified Adenomatous goiter Struma nodosa (simplex) Nodular goiter (nontoxic) NOS 242 Thyrotoxicosis with or without goiter Excludes: neonatal thyrotoxicosis (775.3) ICD-9/Ch03.TXT - pg. 1 242.0 Toxic diffuse goiter Exophthalmic or toxic goiter NOS 242.1 Toxic uninodular goiter Thyroid nodule, toxic or with hyperthyroidism Uninodular goiter, toxic or with hyperthyroidism 242.2 Toxic multinodular goiter 242.3 Toxic nodular goiter, unspecified Any condition in 241.9 specified as toxic or with hyperthyroidism 242.4 Thyrotoxicosis from ectopic thyroid nodule 242.8 Thyrotoxicosis of other specified origin Overproduction of thyroid-stimulating hormone Thyrotoxicosis: factitia from ingestion of excessive thyroid material Use additional E code, if desired, to identify cause, if drug-induced 242.9 Thyrotoxicosis without mention of goiter or other cause Hyperthyroidism NOS 243 Congenital hypothyroidism Congenital thyroid insufficiency Cretinism Use additional code, if desired, to identify associated mental retardation Excludes: congenital (dyshormonogenic) goiter (246.1) 244 Acquired hypothyroidism [Not to be used for underlying cause of death] Includes: hypothyroidism (acquired) myxedema (adult) (juvenile) 244.0 Postsurgical hypothyroidism 244.1 Other postablative hypothyroidism Hypothyroidism following therapy, such as irradiation ICD-9/Ch03.TXT - pg. 2 244.2 Iodine hypothyroidism Hypothyroidism resulting from administration or ingestion of iodide Use additional E code, if desired, to identify drug 244.3 Other iatrogenic hypothyroidism Hypothyroidism resulting from: P-aminosalicylic acid [PAS] Phenylbutazone Resorcinol Use additional E code, if desired, to identify drug 244.8 Other 244.9 Unspecified hypothyroidism Hypothyroidism, primary or NOS Myxedema, primary or NOS 245 Thyroiditis 245.0 Acute thyroiditis Abscess of thyroid Thyroiditis: pyogenic suppurative Use additional code, if desired, to identify organism 245.1 Subacute thyroiditis Thyroiditis: de Quervain's giant-cell granulomatous 245.2 Chronic lymphocytic thyroiditis Autoimmune thyroiditis Lymphocytic thyroiditis (chronic) Hashimoto's disease Struma lymphomatosa 245.3 Chronic fibrous thyroiditis Thyroiditis: ligneous Riedel's ICD-9/Ch03.TXT - pg. 3 245.4 Iatrogenic thyroiditis Use additional code, if desired, to identify cause 245.8 Other and unspecified chronic thyroiditis Chronic thyroiditis NOS 245.9 Unspecified Thyroiditis NOS 246 Other disorders of thyroid 246.0 Disorders of thyrocalcitonin secretion Hypersecretion of calcitonin or thyrocalcitonin 246.1 Dyshormonogenic goiter Congenital goiter Goiter due to enzyme defect in synthesis of thyroid hormone 246.2 Cyst of thyroid Excludes: cystadenoma (226) 246.3 Hemorrhage and infarction of thyroid 246.8 Other Abnormality of thyroid-binding globulin Atrophy of thyroid 246.9 Unspecified DISEASES OF OTHER ENDOCRINE GLANDS (250-259) 250 Diabetes mellitus Excludes: neonatal diabetes mellitus (775.1) nonclinical diabetes (790.2) when complicating pregnancy, childbirth, or the puerperium (648.0) 250.0 Diabetes mellitus without mention of complication Diabetes mellitus without mention of complication or manifestation classifiable to 250.1-250.9 Diabetes (mellitus) NOS ICD-9/Ch03.TXT - pg. 4 250.1 Diabetes with ketoacidosis Diabetic: acidosis without mention of coma ketosis without mention of coma 250.2 Diabetes with coma Diabetic coma (with ketoacidosis) Diabetes with hyperosmolar coma 250.3 Diabetes with renal manifestations Diabetic nephropathy Intercapillary glomerulosclerosis Kimmelstiel-Wilson syndrome 250.4 Diabetes with ophthalmic manifestations Diabetic: cataract retinopathy 250.5 Diabetes with neurological manifestations Diabetic: Diabetic polyneuropathy amyotrophy mononeuropathy 250.6 Diabetes with peripheral circulatory disorders Diabetic: gangrene peripheral angiopathy 250.7 Diabetes with other specified manifestations Excludes: intercurrent infections in diabetic patients 250.9 Diabetes with unspecified complications 251 Other disorders of pancreatic internal secretion 251.0 Hypoglycemic coma Iatrogenic hyperinsulinism Insulin coma Use additional E code, if desired, to identify cause, if drug-induced 251.1 Other hyperinsulinism ICD-9/Ch03.TXT - pg. 5 Hyperinsulinism: Hyperplasia of pancreatic islet beta cells NOS NOS ectopic functional 251.2 Hypoglycemia, unspecified 251.3 Postsurgical hypoinsulinemia [Not to be used for underlying cause of death] Postpancreatectomy hyperglycemia 251.4 Abnormality of secretion of glucagon Hyperplasia of pancreatic islet alpha cells with glucagon excess 251.5 Abnormality of secretion of gastrin Hyperplasia of pancreatic alpha cells with gastrin excess Zollinger-Ellison syndrome 251.8 Other 251.9 Unspecified Islet cell hyperplasia NOS 252 Disorders of parathyroid gland 252.0 Hyperparathyroidism Hyperplasia of parathyroid Osteitis fibrosa cystica generalisata [von Recklinghausen's disease of bone] Excludes: secondary hyperparathyroidism (of renal origin) (588.8) 252.1 Hypoparathyroidism Parathyroiditis (autoimmune) Tetany: parathyroid parathyroprival Excludes: pseudohypoparathyroidism (275.4) pseudopseudohypoparathyroidism (275.4) tetany NOS (781.7) transitory neonatal hypoparathyroidism (775.4) 252.8 Other 252.9 Unspecified ICD-9/Ch03.TXT - pg. 6 253 Disorders of the pituitary gland and its hypothalamic control Includes: the listed conditions whether the disorder is in the pituitary or the hypothalamus Excludes: Cushing's syndrome (255.0) 253.0 Acromegaly and gigantism Arthropathy associated with acromegaly Overproduction of growth hormone 253.1 Other anterior pituitary hyperfunction Excludes: overproduction of: ACTH (255.3) thyroid-stimulating hormone (242.8) 253.2 Panhypopituitarism Cachexia, pituitary Necrosis of pituitary (post-partum) Pituitary insufficiency NOS Sheehan's syndrome Simmonds's disease Excludes: iatrogenic hypopituitarism (253.7) 253.3 Pituitary dwarfism Isolated deficiency of growth hormone Lorain-Levi dwarfism 253.4 Other anterior pituitary disorders Isolated or partial deficiency of an anterior pituitary hormone, other than growth hormone 253.5 Diabetes insipidus Excludes: nephrogenic diabetes insipidus (588.1) 253.6 Other disorders of neurohypophysis Syndrome of inappropriate secretion of antidiuretic hormone 253.7 Iatrogenic pituitary disorders Hypopituitarism: hormone-induced hypophysectomy-induced radiotherapy-induced ICD-9/Ch03.TXT - pg. 7 Use additional E code, if desired, to identify cause 253.8 Other disorders of the pituitary and other syndromes of diencephalohypophyseal origin Abscess of pituitary Cyst of Rathke's pouch Adiposogenital dystrophy Fr”hlich's syndrome 253.9 Unspecified Dyspituitarism 254 Diseases of thymus gland Excludes: aplasia or dysplasia with immunodeficiency (279.2) myasthenia gravis (358.0) 254.0 Persistent hyperplasia of thymus Hypertrophy of thymus 254.1 Abscess of thymus 254.8 Other 254.9 Unspecified 255 Disorders of adrenal glands Includes: the listed conditions whether the basic disorder is in the adrenals or is pituitary induced 255.0 Cushing's syndrome: Cushing's syndrome: NOS iatrogenic idiopathic pituitary-dependent Ectopic ACTH syndrome Overproduction of cortisol Use additional E code, if desired, to identify cause, if drug-induced 255.1 Hyperaldosteronism Conn's syndrome 255.2 Adrenogenital disorders Adrenogenital syndromes, virilizing or feminizing, whether acquired or associated with congenital adrenal hyperplasia consequent on inborn enzyme defects in hormone synthesis ICD-9/Ch03.TXT - pg. 8 Adrenogenital syndrome Female adrenal pseudohermaphroditism Male: macrogenitosomia praecox sexual precocity with adrenal hyperplasia Virilization (female) 255.3 Other corticoadrenal overactivity Overproduction of ACTH 255.4 Corticoadrenal insufficiency Addisonian crisis Addison's disease: NOS tuberculous Adrenal: atrophy (autoimmune) calcification crisis hemorrhage infarction insufficiency NOS 255.5 Other adrenal hypofunction 255.6 Medulloadrenal hyperfunction Catecholamine secretion by pheochromocytoma Note: Not to be used as the primary code for phaeochromocytoma. See note at beginning of Chapter III. 255.8 Other Abnormality of cortisol-binding globulin 255.9 Unspecified 256 Ovarian dysfunction 256.0 Hyperestrogenism 256.1 Other ovarian hyperfunction Hypersecretion of ovarian androgens 256.2 Postablative ovarian failure Ovarian failure: iatrogenic postirradiation postsurgical ICD-9/Ch03.TXT - pg. 9 256.3 Other ovarian failure Premature menopause NOS Primary ovarian failure 256.4 Polycystic ovaries Stein-Leventhal syndrome 256.8 Other 256.9 Unspecified 257 Testicular dysfunction 257.0 Testicular hyperfunction Hypersecretion of testicular hormones 257.1 Postablative testicular hypofunction Testicular hypofunction: iatrogenic postirradiation postsurgical 257.2 Other testicular hypofunction Defective biosynthesis of testicular androgen Testicular hypogonadism Excludes: azoospermia (606.0) 257.8 Other Goldberg-Maxwell syndrome Male pseudohermaphroditism with testicular feminization Testicular feminization 257.9 Unspecified 258 Polyglandular dysfunction and related disorders 258.0 Polyglandular activity in multiple endocrine adenomatosis Wermer's syndrome Note: Not to be used as the primary code for multiple endocrine adenomatosis. See note at beginning of Chapter III. 258.1 Other combinations of endocrine dysfunction Lloyd's syndrome Schmidt's syndrome ICD-9/Ch03.TXT - pg. 10 258.8 Other 258.9 Polyglandular dysfunction, unspecified 259 Other endocrine disorders 259.0 Delay in sexual development and puberty, not elsewhere classified Delayed puberty 259.1 Precocious sexual development and puberty, not elsewhere classified Sexual precocity: NOS constitutional cryptogenic idiopathic 259.2 Carcinoid syndrome Hormone secretion by carcinoid tumors Note: Not to be used as the primary code for carcinoid tumor. See note at beginning of Chapter III. 259.3 Ectopic hormone secretion, not elsewhere classified 259.4 Dwarfism, not elsewhere classified Dwarfism: NOS constitutional Excludes: dwarfism: achondroplastic (756.4) intrauterine (759.7) nutritional (263.2) pituitary (253.3) renal (588.0) progeria (259.8) 259.8 Other Pineal gland dysfunction Werner's syndrome Progeria 259.9 Unspecified Disturbance: endocrine NOS hormone NOS Infantilism NOS ICD-9/Ch03.TXT - pg. 11 NUTRITIONAL DEFICIENCIES (260-269) Excludes: deficiency anemias (280.-, 281.-) 260 Kwashiorkor Nutritional edema with dyspigmentation of skin and hair 261 Nutritional marasmus Nutritional atrophy Severe calorie deficiency Severe malnutrition NOS 262 Other severe protein-calorie malnutrition Malnutrition of third degree according to Gomez classification [weight for age less than 60% of standard] Nutritional edema without mention of dyspigmentation of skin and hair 263 Other and unspecified protein-calorie malnutrition 263.0 Malnutrition of moderate degree Malnutrition of second degree according to Gomez classification [weight for age 60% to less than 75% of standard] 263.1 Malnutrition of mild degree Malnutrition of first degree according to Gomez classification [weight for age 75% to less than 90% of standard] 263.2 Arrested development following protein-calorie malnutrition Nutritional dwarfism Physical retardation due to malnutrition 263.8 Other protein-calorie malnutrition 263.9 Unspecified Dystrophy due to malnutrition Malnutrition (calorie) NOS Excludes: nutritional deficiency NOS (269.9) 264 Vitamin A deficiency 264.0 With conjunctival xerosis 264.1 With conjunctival xerosis and Bitot's spot Bitot's spot in the young child 264.2 With corneal xerosis ICD-9/Ch03.TXT - pg. 12 264.3 With corneal ulceration and xerosis 264.4 With keratomalacia 264.5 With night blindness 264.6 With xerophthalmic scars of cornea 264.7 Other ocular manifestations of vitamin A deficiency Xerophthalmia due to vitamin A deficiency 264.8 Other manifestations of vitamin A deficiency Follicular keratosis due to vitamin A deficiency Xeroderma due to vitamin A deficiency 264.9 Unspecified Hypovitaminosis A NOS 265 Thiamine and niacin deficiency states 265.0 Beriberi 265.1 Other and unspecified manifestations of thiamine deficiency Other vitamin B1 deficiency states 265.2 Pellagra Deficiency: niacin (-tryptophan) nicotinamide nicotinic acid vitamin PP Pellagra (alcoholic) 266 Deficiency of B-complex components 266.0 Ariboflavinosis Riboflavin deficiency 266.1 Vitamin B6 deficiency Deficiency: pyridoxal pyridoxamine pyridoxine Vitamin B6 deficiency syndrome Excludes: vitamin B6-responsive sideroblastic anemia (285.0) ICD-9/Ch03.TXT - pg. 13 266.2 Other B-complex deficiencies Deficiency: cyanocobalamin folic acid vitamin B12 Excludes: deficiency anemias (281.-) 266.9 Unspecified vitamin B deficiency 267 Ascorbic acid deficiency Deficiency of vitamin C Scurvy Excludes: scorbutic anemia (281.8) 268 Vitamin D deficiency Excludes: vitamin D-resistant rickets and osteomalacia (275.3) 268.0 Rickets, active Excludes: coeliac rickets (579.0) renal rickets (588.0) 268.1 Rickets, late effect Any condition specified as rachitic or due to rickets and present one year or more after onset, or stated to be a late effect or sequela of rickets 268.2 Osteomalacia 268.9 Unspecified Avitaminosis D 269 Other nutritional deficiencies 269.0 Deficiency of vitamin K Excludes: deficiency of coagulation factor due to vitamin K deficiency (286.7) vitamin K deficiency of newborn (776.0) 269.1 Deficiency of other vitamins Deficiency: vitamin E vitamin P 269.2 Unspecified vitamin deficiency ICD-9/Ch03.TXT - pg. 14 269.3 Mineral deficiency, not elsewhere classified Excludes: deficiency: potassium (276.8) sodium (276.1) 269.8 Other nutritional deficiency Excludes: failure to thrive (783.4) feeding problems (783.3) newborn (779.3) 269.9 Unspecified OTHER METABOLIC DISORDERS AND IMMUNITY DISORDERS (270-279) Use additional code, if desired, to identify any associated mental retardation 270 Disorders of amino-acid transport and metabolism Excludes: abnormal findings without manifest disease (791-796) disorders of purine and pyrimidine metabolism (277.2) gout (274.-) 270.0 Disturbances of amino-acid transport Cystinosis Glycinuria (renal) Cystinuria Hartnup disease Fanconi (-de Toni) (-Debr82) syndrome 270.1 Phenylketonuria Hyperphenylalaninemia 270.2 Other disturbances of aromatic amino-acid metabolism Albinism Hypertyrosinemia Alkaptonuria Oasthouse urine disease Disturbances of metabolism of Ochronotic arthritis tyrosine and tryptophan Tyrosinosis Hydroxykynureninuria Tyrosinuria Excludes: vitamin B6-deficiency syndrome (266.1) 270.3 Disturbances of branched-chain amino-acid metabolism Disturbances of metabolism of leucine, isoleucine, and valine Hypervalinemia Leucinosis Maple syrup urine disease ICD-9/Ch03.TXT - pg. 15 270.4 Disturbances of sulphur-bearing amino-acid metabolism Cystathioninuria Homocystinuria Disturbances of metabolism of Hypermethioninemia methionine, homocystine, and cystathionine 270.5 Disturbances of histidine metabolism Histidinemia Hyperhistidinemia Imidazole amino aciduria 270.6 Disorders of urea cycle metabolism Argininosuccinic aciduria Hyperammonemia Citrullinemia Hyperornithinemia Disorders of metabolism of ornithine, citrulline, argininosuccinic acid, arginine, and ammonia 270.7 Other disturbances of straight-chain amino-acid metabolism Hyperglycinemia Other disturbances of metabolism of Hyperlysinemia glycine, threonine, serine, Pipecolic acidemia glutamine, and lysine Saccharopinuria 270.8 Other Ethanolaminuria Iminoacidopathy Hydroxyprolinemia Sarcosinemia Hyperprolinemia 270.9 Unspecified 271 Disorders of carbohydrate transport and metabolism Excludes: abnormality of secretion of glucagon (251.4) diabetes mellitus (250.-) hypoglycemia NOS (251.2) mucopolysaccharidosis (277.5) 271.0 Glycogenosis Glycogen-storage disease 271.1 Galactosemia 271.2 Hereditary fructose intolerance ICD-9/Ch03.TXT - pg. 16 271.3 Intestinal disaccharidase deficiencies and disaccharide malabsorption Intolerance or malabsorption (congenital): glucose-galactose lactose sucrose-isomaltose 271.4 Renal glycosuria Renal diabetes 271.8 Other Hyperoxaluria (primary) Oxalosis 271.9 Unspecified 272 Disorders of lipoid metabolism Excludes: localized cerebral lipidoses (330.1) 272.0 Pure hypercholesterolemia Familial hypercholesterolemia Fredrickson's Type IIa hyperlipoproteinemia Hyper-beta-lipoproteinemia Hyperlipidemia, Group A Low-density-lipoid-type [LDL] hyperlipoproteinemia 272.1 Pure hyperglyceridemia Endogenous hyperglyceridemia Fredrickson's Type IV hyperlipoproteinemia Hyperlipidemia, Group B Hyper-pre-beta-lipoproteinemia Hypertriglyceridemia, essential Very-low-density-lipoid-type [VLDL] hyperlipoproteinemia 272.2 Mixed hyperlipidemia Broad- or floating-beta-lipoproteinemia Fredrickson's Type IIb or III hyperlipoproteinemia Hypercholesterolemia with endogenous hyperglyceridemia Hyper-beta-lipoproteinemia with pre-beta-lipoproteinemia Hyperlipidaemia, Group C Tubo-eruptive xanthoma Xanthoma tuberosum 272.3 Hyperchylomicronemia Fredrickson's type I or V Hyperlipidemia, Group D hyperlipoproteinemia Mixed hyperglyceridemia ICD-9/Ch03.TXT - pg. 17 272.4 Other and unspecified hyperlipidemia Alpha-lipoproteinemia Hyperlipidemia NOS Combined hyperlipidemia 272.5 Lipoprotein deficiencies A-beta-lipoproteinemia Hypo-beta-lipoproteinemia (familial High-density lipoid deficiency Lecithin cholesterol acyltransferase Hypo-alpha-lipoproteinemia deficiency Tangier disease 272.6 Lipodystrophy Barraquer-Simons disease Progressive lipodystrophy Use additional E code, if desired, to identify cause, if iatrogenic Excludes: intestinal lipodystrophy (040.2) 272.7 Lipidoses Chemically induced lipidosis Disease: Disease: pseudo-Hurler's or mucolipidosis III Anderson's Sandhoff's Fabry's triglyceride-storage, Type I or II Gaucher's Wolman's or triglyceride-storage, I-cell or mucolipidosis I Type III lipoid-storage NOS Mucolipidosis II Niemann-Pick Primary familial xanthomatosis 272.8 Other disorders of lipoid metabolism Hoffa's disease or liposynovitis prepatellaris Launois-Bensaude's lipomatosis 272.9 Unspecified disorders of lipoid metabolism 273 Disorders of plasma protein metabolism Excludes: agammaglobulinemia and hypogammaglobulinemia (279.-) coagulation defects (286.-) hereditary hemolytic anemias (282.-) 273.0 Polyclonal hypergammaglobulinemia Waldenstr”m's hypergammaglobulinemic purpura: 273.1 Monoclonal paraproteinemia Monoclonal gammopathy: NOS associated with lymphoplasmacytic dyscrasias ICD-9/Ch03.TXT - pg. 18 benign Paraproteinemia: benign (familial) secondary to malignant or inflammatory disease 273.2 Other paraproteinemias Cryoglobulinemic: purpura vasculitis Mixed cryoglobulinemia 273.3 Macroglobulinemia Macroglobulinemia (idiopathic) (primary) Waldenstr”m's macroglobulinemia 273.8 Other Abnormality of transport protein Bisalbuminemia 273.9 Unspecified 274 Gout Excludes: lead gout (984.-) 274.0 Gouty arthropathy 274.1 Gouty nephropathy Gouty nephropathy NOS Uric acid nephrolithiasis 274.8 Gout with other manifestations Gouty tophi of: ear heart 274.9 Gout, unspecified 275 Disorders of mineral metabolism Excludes: abnormal findings without clinical significance (790.-) 275.0 Disorders of iron metabolism Hemochromatosis Excludes: anemia: iron deficiency (280.-) sideroblastic (285.0) ICD-9/Ch03.TXT - pg. 19 275.1 Disorders of copper metabolism Hepatolenticular degeneration Wilson's disease 275.2 Disorders of magnesium metabolism Hypermagnesemia Hypomagnesemia 275.3 Disorders of phosphorus metabolism Familial hypophosphatemia Hypophosphatasia Vitamin D-resistant: osteomalacia rickets 275.4 Disorders of calcium metabolism Calcinosis Nephrocalcinosis Hypercalcemia Pseudohypoparathyroidism Hypercalcinuria Pseudopseudohypoparathyroidism Excludes: parathyroid disorders (252.-) vitamin D deficiency (268.-) 275.8 Other 275.9 Unspecified 276 Disorders of fluid, electrolyte, and acid-base balance Excludes: diabetes insipidus (253.5) familial periodic paralysis (359.3) 276.0 Hyperosmolality and/or hypernatremia Na excess Na overload 276.1 Hyposmolality and/or hyponatremia Na deficiency 276.2 Acidosis Acidosis: NOS lactic metabolic respiratory Excludes: diabetic acidosis (250.1) ICD-9/Ch03.TXT - pg. 20 276.3 Alkalosis Alkalosis: NOS metabolic respiratory 276.4 Mixed acid-base balance disorder 276.5 Volume depletion Dehydration Depletion of volume of plasma or extracellular fluid Hypovolemia Excludes: hypovolemic shock: postoperative (998.0) traumatic (958.4) 276.6 Fluid overload Fluid retention 276.7 Hyperpotassemia K overload K excess 276.8 Hypopotassemia K deficiency 276.9 Electrolyte and fluid disorders not elsewhere classified Electrolyte imbalance Hypochloremia Hyperchloremia Excludes: electrolyte imbalance: associated with hyperemesis gravidarum (643.1) following abortion and ectopic or molar pregnancy (634-638 with fourth digit .4, 639.4) 277 Other and unspecified disorders of metabolism 277.0 Cystic fibrosis Fibrocystic disease of the pancreas Mucoviscidosis 277.1 Disorders of porphyrin metabolism Porphyria Porphyrinuria 277.2 Other disorders of purine and pyrimidine metabolism ICD-9/Ch03.TXT - pg. 21 Hypoxanthine-guanine-phosphoribosyltransferase deficiency [HG-PRT deficiency] Lesch-Nyhan syndrome Excludes: gout (274.-) oroticaciduric anemia (281.4) 277.3 Amyloidosis Amyloidosis: NOS inherited systemic nephropathic neuropathic (Portuguese) (Swiss) secondary Familial Mediterranean fever Hereditary cardiac amyloid 277.4 Disorders of bilirubin excretion Syndrome: Crigler-Najjar Dubin-Johnson Gilbert's Rotor's Excludes: hyperbilirubinemias specific to the perinatal period (774.-) 277.5 Mucopolysaccharidosis Gargoylism Hurler's syndrome Hunter's syndrome 277.6 Other deficiencies of circulating enzymes Alpha 1-antitrypsin deficiency Hereditary angioedema 277.8 Other 277.9 Unspecified 278 Obesity and other hyperalimentation Excludes: hyperalimentation NOS (783.6) poisoning by vitamin preparations (963.5) 278.0 Obesity Excludes: adiposogenital dystrophy (253.8) obesity of endocrine origin NOS (259.9) 278.1 Localized adiposity Fat pad ICD-9/Ch03.TXT - pg. 22 278.2 Hypervitaminosis A 278.3 Hypercarotinemia 278.4 Hypervitaminosis D 278.8 Other 279 Disorders involving the immune mechanism 279.0 Deficiency of humoral immunity Agammaglobulinaemia: Hypogammaglobulinaemia NOS brulous 279.1 Deficiency of cell-mediated immunity Di George syndrome Wiskott-Aldrich syndrome Nezelof syndrome Excludes: ataxia-telangiectasia (334.8) 279.2 Combined immunity deficiency Agammaglobulinemia, Swiss type Combined immunity deficiency syndrome Reticular dysgenesis Thymic: alymphoplasia aplasia or dysplasia with immunodeficiency 279.3 Unspecified immunity deficiency 279.4 Autoimmune disease, not elsewhere classified Autoimmune disease NOS 279.8 Other 279.9 Unspecified ICD-9/Ch03.TXT - pg. 23

59. EMedicine - Ovarian Insufficiency : Article By Lawrence M Nelson, MD, MBA In the US Premature ovarian failure, ie, stage 4 primary ovarian Most patients who develop premature ovarian failure (stage 4 primary ovarian http://www.emedicine.com/med/topic3374.htm

(advertisement) Home Specialties Resource Centers CME ... Patient Education Articles Images CME Patient Education Advanced Search Consumer Health Link to this site Back to: eMedicine Specialties Medicine, Ob/Gyn, Psychiatry, and Surgery Obstetrics/gynecology Ovarian Insufficiency Last Updated: May 17, 2005 Rate this Article Email to a Colleague Synonyms and related keywords: premature ovarian failure, premature menopause, autoimmune ovarian failure, autoimmune oophoritis, reduced ovarian reserve, hypergonadotropic amenorrhea, menopause, perimenopause, Turner syndrome, gonadal dysgenesis, hyperprolactinemia, hypothalamic amenorrhea, polycystic ovary syndrome, Stein-Leventhal syndrome, primary amenorrhea, secondary amenorrhea, oligomenorrhea, metrorrhagia, polymenorrhea, amenorrhea AUTHOR INFORMATION Section 1 of 10 Author Information Introduction Clinical Differentials ... Bibliography Author: Lawrence M Nelson, MD, MBA , Head of Gynecologic Endocrinology Unit, Investigator, Section of Women's Health Research, Developmental Endocrinology Branch, National Institutes of Health Coauthor(s): Vladimir Bakalov, MD

60. Premature Ovarian Failure (POF) Premature ovarian failure (POF) Some health care providers also use the term primary ovarian insufficiency to describe this condition. http://catalog.nucleusinc.com/displaymonograph.php?MID=153

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 90    Back | 1  | 2  | 3  | 4  | 5  | Next 20